Keynote Presentations
 | Aim and Scope of Prenatal Screening: The Autonomy Paradigm and Its Limits Wybo Dondorp, Ph.D., Maastricht University |  | 25 Years of Chromosomal PGD and Counting Darren K. Griffin, Ph.D., DSc, University of Kent |
 | Hurricane Watch: Use of Novel Technologies for Early Detection and Identification of Multi-Resistant Bacteria Ulf B. Goebel, M.D., Ph.D., Charité, University Medicine Berlin |  | Impact of POCT Technology on Efficiency and Effectiveness of Clinical Processes Wilfried von Eiff, Ph.D., Leipzig Graduate School of Management |
 | Clinical Implications of CTCs Analysis Klaus Pantel, M.D., University Medical Center Hamburg-Eppendorf |  | Novel Methods for Enrichment of Mutations and Differentially Methylated Sequences from Liquid Biopsy Genomes G. Mike Makrigiorgos, Ph.D., Dana Farber and Harvard Medical School |
Novel molecular-based tools are rapidly entering the clinic and creating a new paradigm in healthcare. The Fourth International Molecular Diagnostics Europe event will return to Lisbon this spring and feature six tracks: Prenatal Molecular Diagnostics, Reproductive Genetic Diagnostics, Circulating Tumour Cells, Circulating Cell-Free DNA, Advanced Diagnostics for Infectious Disease, and Point-of-Care Diagnostics. As the prenatal diagnostics market has demonstrated, molecular diagnostics are being applied to the clinical setting for greater speed and accuracy of healthcare delivery, while paving the way for a new era in medicine.